|
Synonyms: Ampligen | Atoven | Poly I: Poly C12U
Compound class:
Nucleic acid
Comment: Rintatolimod is a double-stranded RNA oligonucleotide that is intended to act as a Toll-like receptor 3 (TLR3) agonist [1].
Full sequence is: poly[5')-inosinylyl-(3'→] duplex with poly[dodecakis[3')-cytidylyl- (5'→]3')-uridylyl-(5'→], which is similar to prototypical RNA poly I:C. |
| References |
|
1. Adis Editorial. (2004)
Mismatched double-stranded RNA: polyI:polyC12U. Drugs R D, 5 (5): 297-304. [PMID:15357629] |
|
2. Essey RJ, McDougall BR, Robinson Jr WE. (2001)
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Res, 51 (3): 189-202. [PMID:11448730] |
|
3. Haddaoui HE, van Eijck CW, Doukas M, van den Bosch TP, van Koetsveld PM, Hofland LJ, Mustafa DA, van Eijck CH. (2023)
Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. Am J Cancer Res, 13 (6): 2657-2669. [PMID:37424830] |
|
4. Jasani B, Navabi H, Adams M. (2009)
Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine, 27 (25-26): 3401-4. [PMID:19200817] |
|
5. Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL, Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM. (2012)
A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One, 7 (3): e31334. [PMID:22431963] |
|
6. Strayer DR, Young D, Mitchell WM. (2020)
Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS One, 15 (10): e0240403. [PMID:33119613] |
|
7. Thompson KA, Strayer DR, Salvato PD, Thompson CE, Klimas N, Molavi A, Hamill AK, Zheng Z, Ventura D, Carter WA. (1996)
Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis, 15 (7): 580-7. [PMID:8874076] |
|
8. van Eijck CWF, Haddaoui HE, Kucukcelebi S, Vadgama D, Fellah A, Mustafa DAM, Aerts JGJV, van Eijck CHJ, Willemsen M. (2024)
Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. Clin Cancer Res, 30 (16): 3447-3458. [PMID:38488815] |
|
9. Yong SJ, Halim A, Halim M, Ming LC, Goh KW, Alfaresi M, AlShehail BM, Al Fares MA, Alissa M, Sulaiman T et al.. (2023)
Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review. Expert Opin Investig Drugs, 32 (7): 655-667. [PMID:37534972] |